Loading clinical trials...

PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness | Clinical Trials | Clareo Health

SUSPENDEDNA

PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness

The Paradigm IV Trial - PFx Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness

NCT00529945•Cierra

View on ClinicalTrials.gov

Summary

The primary object of this study is to demonstrate the continued safety and performance of the PFx Closure System when utilized for patients with PFOs suffering from cryptogenic stroke, transient ischemic attack, migraine or decompression illness.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 18 to 65 years old
•PFO with one or more of:
•* Cryptogenic stroke,
•* TIA or embolism,
•* History of severe migraine headaches, or
•* History of severe decompression illness.

Exclusion Criteria

•In appropriate anatomy (vascular or cardiac) or inappropriate medical condition for PFO closure and study medications.

Locations (1)

Cardiovascular Center Frankfurt Sankt katharinen

Frankfurt, Germany

Key Dates

Start Date

August 1, 2007

Completion Date

December 1, 2007

Last Updated

December 21, 2007

Enrollment

200

ESTIMATED participants

Conditions

PFOStrokeTransient Ischemic AttackMigraineDecompression Illness

Interventions

PFx Closure System

DEVICE

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants

NCT07371455

Ischemic Stroke

View study

RECRUITINGNA

Effects of Circuit Training Combining Different Types of Distal Robot-assisted and Task-oriented Therapy on Motor Control, Motor and Daily Functions, and Quality of Life After Stroke

NCT06258538

Stroke Patients

View study

RECRUITINGNA

Cerebellar Stimulation for Aphasia Rehabilitation

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 21, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants

Effects of Circuit Training Combining Different Types of Distal Robot-assisted and Task-oriented Therapy on Motor Control, Motor and Daily Functions, and Quality of Life After Stroke

Cerebellar Stimulation for Aphasia Rehabilitation

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

Rapid Evacuation and Access of Cerebral Hemorrhage Trial

Mirror Therapy Rehabilitation of the Upper Limb After Stroke (NEURO-MIROIR 2)